Effects of risedronate on osteoarthritis of the knee

Jun Iwamoto, Tsuyoshi Takeda, Yoshihiro Sato, Hideo Matsumoto

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The purpose of the present study was to discuss the effects of risedronate on osteoarthritis (OA) of the knee by reviewing the existing literature. The literature was searched with PubMed, with respect to prospective, double-blind, randomized placebo-controlled trials (RCTs), using the following search terms: risedronate, knee, and osteoarthritis. Two RCTs met the criteria. A RCT (n = 231) showed that risedronate treatment (15 mg/day) for 1 year improved symptoms. A larger RCT (n = 1,896) showed that risedronate treatment (5 mg/day, 15 mg/day, 35 mg/week, and 50 mg/week) for 2 years did not improve signs or symptoms, nor did it alter radiological progression. However, a subanalysis study (n = 477) revealed that patients with marked cartilage loss preserved the structural integrity of subchondral bone by risedronate treatment (15 mg/day and 50 mg/week). Another subanalysis study (n = 1,885) revealed that C-terminal crosslinking telopeptide of type II collagen (CTX-II) decreased with risedronate treatment in a dose-dependent manner, and levels reached after 6 months were associated with radiological progression at 2 years. The results of these RCTs show that risedronate reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone. The review of the literature suggests that higher doses of risedronate (15 mg/day) strongly reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.

Original languageEnglish
Pages (from-to)164-170
Number of pages7
JournalYonsei Medical Journal
Volume51
Issue number2
DOIs
Publication statusPublished - 2010 Mar

Fingerprint

Knee Osteoarthritis
Randomized Controlled Trials
Placebos
Cartilage
Bone and Bones
Osteoarthritis
Collagen Type II
Risedronate Sodium
Therapeutics
PubMed
Signs and Symptoms

Keywords

  • Bisphosphonate
  • Knee
  • Osteoarthritis
  • Subchondral bone

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Iwamoto, J., Takeda, T., Sato, Y., & Matsumoto, H. (2010). Effects of risedronate on osteoarthritis of the knee. Yonsei Medical Journal, 51(2), 164-170. https://doi.org/10.3349/ymj.2010.51.2.164

Effects of risedronate on osteoarthritis of the knee. / Iwamoto, Jun; Takeda, Tsuyoshi; Sato, Yoshihiro; Matsumoto, Hideo.

In: Yonsei Medical Journal, Vol. 51, No. 2, 03.2010, p. 164-170.

Research output: Contribution to journalArticle

Iwamoto, J, Takeda, T, Sato, Y & Matsumoto, H 2010, 'Effects of risedronate on osteoarthritis of the knee', Yonsei Medical Journal, vol. 51, no. 2, pp. 164-170. https://doi.org/10.3349/ymj.2010.51.2.164
Iwamoto, Jun ; Takeda, Tsuyoshi ; Sato, Yoshihiro ; Matsumoto, Hideo. / Effects of risedronate on osteoarthritis of the knee. In: Yonsei Medical Journal. 2010 ; Vol. 51, No. 2. pp. 164-170.
@article{47fb7a3ccc6043109aa1be1d5ed06085,
title = "Effects of risedronate on osteoarthritis of the knee",
abstract = "The purpose of the present study was to discuss the effects of risedronate on osteoarthritis (OA) of the knee by reviewing the existing literature. The literature was searched with PubMed, with respect to prospective, double-blind, randomized placebo-controlled trials (RCTs), using the following search terms: risedronate, knee, and osteoarthritis. Two RCTs met the criteria. A RCT (n = 231) showed that risedronate treatment (15 mg/day) for 1 year improved symptoms. A larger RCT (n = 1,896) showed that risedronate treatment (5 mg/day, 15 mg/day, 35 mg/week, and 50 mg/week) for 2 years did not improve signs or symptoms, nor did it alter radiological progression. However, a subanalysis study (n = 477) revealed that patients with marked cartilage loss preserved the structural integrity of subchondral bone by risedronate treatment (15 mg/day and 50 mg/week). Another subanalysis study (n = 1,885) revealed that C-terminal crosslinking telopeptide of type II collagen (CTX-II) decreased with risedronate treatment in a dose-dependent manner, and levels reached after 6 months were associated with radiological progression at 2 years. The results of these RCTs show that risedronate reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone. The review of the literature suggests that higher doses of risedronate (15 mg/day) strongly reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.",
keywords = "Bisphosphonate, Knee, Osteoarthritis, Subchondral bone",
author = "Jun Iwamoto and Tsuyoshi Takeda and Yoshihiro Sato and Hideo Matsumoto",
year = "2010",
month = "3",
doi = "10.3349/ymj.2010.51.2.164",
language = "English",
volume = "51",
pages = "164--170",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "2",

}

TY - JOUR

T1 - Effects of risedronate on osteoarthritis of the knee

AU - Iwamoto, Jun

AU - Takeda, Tsuyoshi

AU - Sato, Yoshihiro

AU - Matsumoto, Hideo

PY - 2010/3

Y1 - 2010/3

N2 - The purpose of the present study was to discuss the effects of risedronate on osteoarthritis (OA) of the knee by reviewing the existing literature. The literature was searched with PubMed, with respect to prospective, double-blind, randomized placebo-controlled trials (RCTs), using the following search terms: risedronate, knee, and osteoarthritis. Two RCTs met the criteria. A RCT (n = 231) showed that risedronate treatment (15 mg/day) for 1 year improved symptoms. A larger RCT (n = 1,896) showed that risedronate treatment (5 mg/day, 15 mg/day, 35 mg/week, and 50 mg/week) for 2 years did not improve signs or symptoms, nor did it alter radiological progression. However, a subanalysis study (n = 477) revealed that patients with marked cartilage loss preserved the structural integrity of subchondral bone by risedronate treatment (15 mg/day and 50 mg/week). Another subanalysis study (n = 1,885) revealed that C-terminal crosslinking telopeptide of type II collagen (CTX-II) decreased with risedronate treatment in a dose-dependent manner, and levels reached after 6 months were associated with radiological progression at 2 years. The results of these RCTs show that risedronate reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone. The review of the literature suggests that higher doses of risedronate (15 mg/day) strongly reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.

AB - The purpose of the present study was to discuss the effects of risedronate on osteoarthritis (OA) of the knee by reviewing the existing literature. The literature was searched with PubMed, with respect to prospective, double-blind, randomized placebo-controlled trials (RCTs), using the following search terms: risedronate, knee, and osteoarthritis. Two RCTs met the criteria. A RCT (n = 231) showed that risedronate treatment (15 mg/day) for 1 year improved symptoms. A larger RCT (n = 1,896) showed that risedronate treatment (5 mg/day, 15 mg/day, 35 mg/week, and 50 mg/week) for 2 years did not improve signs or symptoms, nor did it alter radiological progression. However, a subanalysis study (n = 477) revealed that patients with marked cartilage loss preserved the structural integrity of subchondral bone by risedronate treatment (15 mg/day and 50 mg/week). Another subanalysis study (n = 1,885) revealed that C-terminal crosslinking telopeptide of type II collagen (CTX-II) decreased with risedronate treatment in a dose-dependent manner, and levels reached after 6 months were associated with radiological progression at 2 years. The results of these RCTs show that risedronate reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone. The review of the literature suggests that higher doses of risedronate (15 mg/day) strongly reduces the marker of cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.

KW - Bisphosphonate

KW - Knee

KW - Osteoarthritis

KW - Subchondral bone

UR - http://www.scopus.com/inward/record.url?scp=77649220561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649220561&partnerID=8YFLogxK

U2 - 10.3349/ymj.2010.51.2.164

DO - 10.3349/ymj.2010.51.2.164

M3 - Article

C2 - 20191005

AN - SCOPUS:77649220561

VL - 51

SP - 164

EP - 170

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 2

ER -